Business Context and Reporting Period
Company: Nephros, Inc. (NEPH)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Nephros develops and markets high-performance water filtration solutions, primarily for medical-grade infection control (hospitals, dialysis) and commercial applications (hospitality, food service). The company operates as a single reporting segment.
Key Financial Metrics
| Metric (in thousands) | Q2 2025 | Q2 2024 | YTD 2025 | YTD 2024 |
|---|---|---|---|---|
| Total Net Revenues | $4,419 | $3,252 | $9,296 | $6,774 |
| Gross Margin | $2,795 (63%) | $1,912 (59%) | $5,949 (64%) | $4,099 (61%) |
| Operating Income (Loss) | $248 | $(317) | $814 | $(517) |
| Net Income (Loss) | $237 | $(289) | $795 | $(458) |
| Cash and Cash Equivalents | $5,074 | $3,080 | $5,074 | $3,080 |
| Working Capital | $7,806 | $6,736 | $7,806 | $6,736 |
| Accumulated Deficit | $(143,537) | $(144,864) | $(143,537) | $(144,864) |
Liquidity: The company generated positive operating cash flow of $1.3 million for the six months ended June 30, 2025, compared to a use of $1.2 million in the prior year period. Management believes current cash balances are sufficient to fund operations for at least the next 12 months.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 36% in Q2 2025 and 37% YTD 2025 compared to the prior year. Growth was driven by increased programmatic reorders, new active sites, and higher emergency response sales.
- Profitability Turnaround: The company returned to profitability, reporting net income of $237,000 in Q2 2025 and $795,000 YTD, reversing net losses of $289,000 and $458,000 in the respective prior-year periods.
- Margin Expansion: Gross margin improved by 4 percentage points in Q2 (63% vs. 59%) and 3 percentage points YTD (64% vs. 61%), attributed to reduced shipping costs, favorable product mix, and lower inventory reserve adjustments.
- Expense Increases: Selling, general, and administrative (SG&A) expenses rose 13% in Q2 and 9% YTD, primarily due to higher sales commissions, employee bonus accruals, and increased stock-based compensation. R&D expenses increased 22% in Q2 and 30% YTD due to higher headcount and salaries.
Outlook, Risks, and Contingencies
- Outlook: Management expects to continue focusing on sales growth and expense management to maintain profitability. The company anticipates potential step-change increases in commercial market revenue as it expands distribution beyond its former exclusive partner, Donastar.
- Material Weakness: A material weakness in internal controls over financial reporting was identified regarding revenue recognition for contracts with multiple performance obligations (products and services). Management is implementing remediation protocols, including new pricing processes and sales team training.
- Supply Chain Risk: The company relies on Medica S.p.A. as its sole supplier for filter material. The company must meet minimum annual purchase commitments (€4.6 million for 2025) to avoid breach of contract and potential termination.
- Customer Concentration: Two customers (Customer A and Customer B) accounted for 39% of revenue in Q2 2025 and 34% YTD 2025.
- Regulatory & Tax: The company is assessing the impact of the "One Big Beautiful Bill Act" (OBBBA) enacted in July 2025, though the impact is expected to be immaterial.
Investor Verification Checklist
- Sustainability of Profitability: Verify if the Q2 2025 profitability is sustainable given the historical accumulated deficit of $143.5 million.
- Customer Concentration: Assess the risk associated with the top two customers representing nearly 40% of quarterly revenue.
- Supply Agreement Compliance: Confirm the company's ability to meet the €4.6 million minimum purchase commitment for 2025 with its sole supplier, Medica.
- Internal Control Remediation: Monitor the progress of remediation efforts for the material weakness in revenue recognition controls.
- Commercial Market Expansion: Evaluate the success of the new non-exclusive distribution strategy following the end of the exclusive relationship with Donastar.